Right ventricular systolic pressure assessed by echocardiography: A predictive factor of mortality in patients with scleroderma

Clinical Cardiology

Volumn 34, Issue 8, 2011, Pages 488-493

  Kiatchoosakun, Songsak ^a,c   Wongvipaporn, Chaiyasith ^a   Nanagara, Ratanavadee ^a   Hoit, Brian D ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

ACROCYANOSIS; ADULT; ARTICLE; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERICARDIAL EFFUSION; PULMONARY HYPERTENSION; SCLERODERMA; SURVIVAL RATE; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION;

ADULT; BLOOD PRESSURE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; THAILAND; TRICUSPID VALVE INSUFFICIENCY; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 80051553005     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20920     Document Type: Article

References (32)

1. Kahan A, Coghlan G, McLaughlin V., Cardiac complications of systemic sclerosis. Rheumatology (Oxford). 2009; 48 (suppl 3): iii45-iii48.
2. Hinchcliff M, Varga J., Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Physician. 2008; 78: 961-968.
3. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005; 118: 2-10. (Pubitemid 40082450)
4. Wells AU, Steen V, Valentini G., Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford). 2009; 48 (suppl 3): iii40-iii44.
5. McLaughlin V, Humbert M, Coghlan G, et al. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009; 48 (suppl 3): iii25-iii31.
6. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 (12 suppl S): 40S-47S. (Pubitemid 38759716)
7. Borgeson DD, Seward JB, Miller FA, et al. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr. 1996; 9: 832-837.
8. Chotivittayatarakorn P, Pathmanand C, Thisyakorn C, et al. Doppler echocardiographic predictions of pulmonary artery pressure in children with congenital heart disease. J Med Assoc Thai. 1992; 75: 79-84.
9. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler- catheterization study in 127 patients. J Am Coll Cardiol. 1985; 6: 750-756. (Pubitemid 16247620)
10. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997; 36: 239-243.
11. Kowal-Bielecka O, Avouac J, Pittrow D, et al. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol. 2010; 37: 105-115.
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23: 581-590.
13. Devereaux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450-458. (Pubitemid 16119719)
14. Mugerwa JA, Kiatchoosakun S, Restivo J, et al. The myocardial performance index in patients with aortic stenosis. Echocardiography. 2002; 19: 267-272. (Pubitemid 34621005)
15. Dujardin KS, Tei C, Yeo TC, et al. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol. 1998; 82: 1071-1076. (Pubitemid 28507090)
16. Gullulu S, Kaderli AA, Ekbul A, et al. Tissue Doppler echocardiography and myocardial performance index in patients with scleroderma. J Int Med Res. 2005; 33: 417-424. (Pubitemid 41057439)
17. Bland JM, Altman DG., Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1: 307-310. (Pubitemid 16134762)
18. Kumar U, Ramteke R, Yadav R, et al. Prevalence and predictors of pulmonary artery hypertension in systemic sclerosis. J Assoc Physicians India. 2008; 56: 413-417.
19. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology. 2001; 40: 453-459.
20. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52: 3792-3800. (Pubitemid 41798217)
21. Chang B, Wigley FM, White B, et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003; 30: 2398-2405. (Pubitemid 37413900)
22. Schachna L, Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest. 2003; 124: 2098-2104. (Pubitemid 38010575)
23. Ristow B, Ali S, Ren X, et al. Elevated pulmonary artery pressure by Doppler echocardiography predicts hospitalization for heart failure and mortality in ambulatory stable coronary artery disease. J Am Coll Cardiol. 2007; 49: 43-49. (Pubitemid 46026900)
24. Chung L, Krishnan E, Chakravarty EF., Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology. 2007; 46: 1808-1813. (Pubitemid 350168296)
25. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115: 343-349.
26. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009; 60: 569-577.
27. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with pulmonary fibrosis. Chest. 2005; 128: 2393-2399.
28. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr. 1996; 9: 838-847.
29. Yeo TC, Dujardin KS, Tei C, et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol. 1998; 81: 1157-1161. (Pubitemid 28232689)
30. McLaughlin VV., Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest. 2006; 36 (suppl 3): iii10-iii15.
31. Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008; 67: 1222-1228.
32. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006; 65: 1336-1340. (Pubitemid 44620443)